

Yoichi Imai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3802788/publications.pdf>

Version: 2024-02-01

131
papers

3,448
citations

126907

33
h-index

155660

55
g-index

137
all docs

137
docs citations

137
times ranked

4814
citing authors

#	ARTICLE	IF	CITATIONS
1	RUNX1 transactivates <i>BCR-ABL1</i> expression in Philadelphia chromosome positive acute lymphoblastic leukemia. <i>Cancer Science</i> , 2022, 113, 529-539.	3.9	5
2	Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 110.	8.6	16
3	Expression of activated integrin $\alpha 2 \beta 1$ in multiple myeloma patients. <i>International Journal of Hematology</i> , 2021, 114, 3-7.	1.6	8
4	RUNX inhibitor suppresses graft-versus-host disease through targeting RUNX-FATC2 axis. <i>EJHaem</i> , 2021, 2, 449-458.	1.0	1
5	Prognostic impacts of peripheral blood erythroblasts after single-unit cord blood transplantation. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 1437-1442.	1.3	0
6	P30-1 The influence of thiamine declines on neuropsychiatric symptoms in patients with hematological cancer. <i>Annals of Oncology</i> , 2021, 32, S348.	1.2	0
7	Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2142-2150.	2.2	9
8	Thiamine Deficiency and Neurological Symptoms in Patients with Hematological Cancer Receiving Chemotherapy: A Retrospective Analysis. <i>Journal of Neurosciences in Rural Practice</i> , 2021, 12, 726-732.	0.8	1
9	Association between thiamine decrease and neuropsychiatric symptoms in gastrointestinal and hematological cancer patients receiving chemotherapy. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111929.	5.6	3
10	CD155 and CD112 as possible therapeutic targets of <i>FLT3</i> inhibitors for acute myeloid leukemia. <i>Oncology Letters</i> , 2021, 23, 51.	1.8	9
11	Clinical efficacy of haematopoietic stem cell transplantation for adult adrenoleukodystrophy. <i>Brain Communications</i> , 2020, 2, fcz048.	3.3	14
12	Fractionated ifosfamide, carboplatin, and etoposide with rituximab as a safe and effective treatment for relapsed/refractory diffuse large B cell lymphoma with severe comorbidities. <i>Annals of Hematology</i> , 2020, 99, 2577-2586.	1.8	1
13	L-Arginine prevents cereblon-mediated ubiquitination of glucokinase and stimulates glucose-6-phosphate production in pancreatic β -cells. <i>Communications Biology</i> , 2020, 3, 497.	4.4	13
14	Latest Development in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2544.	3.7	4
15	Clinical features and outcomes of adult Langerhans cell histiocytosis: a single-center experience. <i>International Journal of Hematology</i> , 2020, 112, 185-192.	1.6	12
16	SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma. <i>Molecular Cancer Research</i> , 2020, 18, 632-643.	3.4	12
17	The novel multi-cytokine inhibitor TO-207 specifically inhibits pro-inflammatory cytokine secretion in monocytes without affecting the killing ability of CAR T cells. <i>PLoS ONE</i> , 2020, 15, e0231896.	2.5	11
18	UGGT1 retains proinsulin in the endoplasmic reticulum in an arginine dependent manner. <i>Biochemical and Biophysical Research Communications</i> , 2020, 527, 668-675.	2.1	7

#	ARTICLE	IF	CITATIONS
19	High Prevalence of Left Ventricular Non-Compaction and Its Effect on Chemotherapy-Related Cardiac Dysfunction in Patients With Hematological Diseases. <i>Circulation Journal</i> , 2020, 84, 1957-1964.	1.6	3
20	HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action. <i>Cancers</i> , 2019, 11, 475.	3.7	40
21	Nested Polymerase Chain Reaction with Specific Primers for Mucorales in the Serum of Patients with Hematological Malignancies. <i>Japanese Journal of Infectious Diseases</i> , 2019, 72, 196-198.	1.2	1
22	Regulation of Calcineurin Signaling Through Blocking of the Chaperone Function of Hsp90 by HDAC Inhibitors. <i>Heat Shock Proteins</i> , 2019, , 317-328.	0.2	0
23	Therapeutic Targeting of Monokine Production Is a Promising Strategy to Attenuate Cytokine-Release Syndrome in CAR-T Cell Therapy. <i>Blood</i> , 2019, 134, 2067-2067.	1.4	0
24	Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression. <i>Blood</i> , 2019, 134, 4361-4361.	1.4	1
25	Knockdown of the Wnt receptor Frizzled-1 (FZD1) reduces MDR1 /P-glycoprotein expression in multidrug resistant leukemic cells and inhibits leukemic cell proliferation. <i>Leukemia Research</i> , 2018, 67, 99-108.	0.8	20
26	Different clonal dynamics of chronic myeloid leukaemia between bone marrow and the central nervous system. <i>British Journal of Haematology</i> , 2018, 183, 842-845.	2.5	0
27	Secondary Syphilis with Tonsillar and Cervical Lymphadenopathy and a Pulmonary Lesion Mimicking Malignant Lymphoma. <i>American Journal of Case Reports</i> , 2018, 19, 238-243.	0.8	13
28	Chronic inflammatory demyelinating polyneuropathy in adult T-cell leukemia-lymphoma patients following allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1470-1473.	2.4	6
29	Nonmyelomatous Ascites Resulting from the Increased Secretion of Vascular Endothelial Growth Factor in Multiple Myeloma. <i>Internal Medicine</i> , 2018, 57, 725-727.	0.7	0
30	Clinical impact of serum soluble SLAMF7 in multiple myeloma. <i>Oncotarget</i> , 2018, 9, 34784-34793.	1.8	27
31	Histone Deacetylase Inhibitors with or without AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicity As Well As Apoptosis. <i>Blood</i> , 2018, 132, 4435-4435.	1.4	2
32	Serum Soluble SLAMF7 is Correlated With Disease Progression in Multiple Myeloma and May Affect Anti-SLAMF7 Antibody Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e39-e40.	0.4	0
33	Clinical Impact and Possible Immunosuppressive Function of Soluble B7-H1 (PD-L1) in Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e110-e111.	0.4	2
34	Hypersensitivity reaction to β -lactam antibiotics in patients with adult T-cell leukemia/lymphoma treated with mogamulizumab. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2017, 55, 807-810.	0.6	1
35	Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma. <i>JCI Insight</i> , 2016, 1, e85061.	5.0	32
36	Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents era. <i>Annals of Hematology</i> , 2016, 95, 1465-1472.	1.8	11

#	ARTICLE	IF	CITATIONS
37	Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies. <i>Cancer Science</i> , 2016, 107, 1543-1549.	3.9	53
38	Cytomegalovirus reactivation in low-grade B-cell lymphoma patients treated with bendamustine. <i>Leukemia and Lymphoma</i> , 2016, 57, 2204-2207.	1.3	9
39	Post-transplant Lymphoproliferative Disorder in Kidney Transplant Recipients: A Single-Center Experience in Japan. <i>Therapeutic Apheresis and Dialysis</i> , 2016, 20, 165-173.	0.9	5
40	Clinical Profile and BRAF Status of 30 Japanese Patients with Adult Langerhans Cell Histiocytosis. <i>Blood</i> , 2016, 128, 4883-4883.	1.4	1
41	Exploratory Introduction of Cognitive Computing to Clinical Sequencing in Hematological Malignancies. <i>Blood</i> , 2016, 128, 5262-5262.	1.4	0
42	Retrospective Analysis of Treatment Outcomes for Patients with Follicular Lymphoma and Comorbidities. <i>Blood</i> , 2015, 126, 5082-5082.	1.4	0
43	Fractionated ICE with Rituximab Is Safe and Effective for Relapse/Refractory DLBCL Patients with Severe Comorbidities. <i>Blood</i> , 2015, 126, 2713-2713.	1.4	5
44	Intracellular Reactive Oxygen Species Mark and Influence the Megakaryocyte-Erythrocyte Progenitor Fate of Common Myeloid Progenitors. <i>Stem Cells</i> , 2014, 32, 548-557.	3.2	31
45	Donor cell-derived leukemia after cord blood transplantation and a review of the literature: differences between cord blood and BM as the transplant source. <i>Bone Marrow Transplantation</i> , 2014, 49, 102-109.	2.4	28
46	Prospective Analysis of Cytomegalovirus Reactivation and the Immune State of Low-Grade B-Cell Lymphoma Patients Treated with Bendamustine. <i>Blood</i> , 2014, 124, 4411-4411.	1.4	2
47	Interaction Between B7-H1 Molecules on Myeloma Cells and PD-1 Molecules on T Cells Induces Resistance to Antimyeloma Chemotherapy. <i>Blood</i> , 2014, 124, 2018-2018.	1.4	0
48	Clinical Utility of Slam Family Member CD229 in Identifying Tumor Cells and High-Risk Disease Markers, CD86 (B7-2) and CD126 (IL-6 receptor), Using Flow Cytometric Analysis in Multiple Myeloma. <i>Blood</i> , 2014, 124, 2063-2063.	1.4	0
49	Knockdown of a Wnt Receptor FZD1 reduces MDR1/P-Glycoprotein Expression in Human Leukemia Cells through the Wnt/ β -Catenin Signaling Pathway. <i>Blood</i> , 2014, 124, 2225-2225.	1.4	1
50	Successful treatment of secondary NK/T-cell lymphoma of the testis. <i>Annals of Hematology</i> , 2013, 92, 997-998.	1.8	1
51	Transient lupus anticoagulant with a prolonged activated partial thromboplastin time secondary to cytomegalovirus-related infectious mononucleosis. <i>Annals of Hematology</i> , 2013, 92, 143-144.	1.8	4
52	Clinical Significance of Serum-Soluble Interleukin-2 Receptor in Patients With Follicular Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 410-416.	0.4	22
53	Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy. <i>British Journal of Haematology</i> , 2012, 158, 798-800.	2.5	8
54	Multiple phosphorylation sites are important for RUNX1 activity in early hematopoiesis and T-cell differentiation. <i>European Journal of Immunology</i> , 2012, 42, 1044-1050.	2.9	18

#	ARTICLE	IF	CITATIONS
55	The effect of iron overload and chelation on erythroid differentiation. <i>International Journal of Hematology</i> , 2012, 95, 149-159.	1.6	59
56	MLL-HOXA9 and Calcineurin Are Novel Therapeutic Targets in Multiple Myeloma. <i>Blood</i> , 2012, 120, 4007-4007.	1.4	0
57	Evi1 represses PTEN expression and activates PI3K/AKT/mTOR via interactions with polycomb proteins. <i>Blood</i> , 2011, 117, 3617-3628.	1.4	129
58	Loss of AML1/Runx1 accelerates the development of MLL-ENL leukemia through down-regulation of p19ARF. <i>Blood</i> , 2011, 118, 2541-2550.	1.4	31
59	AML1/RUNX1 functions as a cytoplasmic attenuator of NF- κ B signaling in the repression of myeloid tumors. <i>Blood</i> , 2011, 118, 6626-6637.	1.4	54
60	Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. <i>Blood</i> , 2011, 117, 6304-6314.	1.4	79
61	A Case of Myeloid Sarcoma with Correlation to JAK2V617F Mutation, Complicated by Myelofibrosis and Secondary Acute Myeloid Leukemia. <i>Internal Medicine</i> , 2011, 50, 2649-2652.	0.7	10
62	The negative impact of female donor/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk. <i>Transplant International</i> , 2011, 24, 469-476.	1.6	35
63	Fatal amebic colitis after high-dose dexamethasone therapy for newly diagnosed multiple myeloma. <i>Annals of Hematology</i> , 2011, 90, 225-226.	1.8	14
64	Concurrent development of α -Burkitt-like lymphoma and BCL-2-rearranged low-grade B cell lymphoma sharing the same germinal center origin. <i>International Journal of Hematology</i> , 2011, 93, 112-117.	1.6	8
65	Nilotinib-induced hypothyroidism in a patient with chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2011, 93, 400-402.	1.6	15
66	Evi1 is essential for hematopoietic stem cell self-renewal, and its expression marks hematopoietic cells with long-term multilineage repopulating activity. <i>Journal of Experimental Medicine</i> , 2011, 208, 2403-2416.	8.5	157
67	HIV-negative, HHV-8-unrelated primary effusion lymphoma-like lymphoma: report of two cases. <i>American Journal of Hematology</i> , 2010, 85, 85-87.	4.1	23
68	Distinct roles for LFA-1 affinity regulation during T-cell adhesion, diapedesis, and interstitial migration in lymph nodes. <i>Blood</i> , 2010, 115, 1572-1581.	1.4	91
69	A case report of non-traumatic renal artery pseudoaneurysm due to chemotherapy for diffuse large B-cell lymphoma. <i>Annals of Hematology</i> , 2010, 89, 107-108.	1.8	7
70	Reversible posterior leukoencephalopathy syndrome following R-CHOP therapy for diffuse large B-cell lymphoma. <i>Annals of Hematology</i> , 2010, 89, 207-208.	1.8	14
71	High-dose dexamethasone therapy for severe thrombocytopenia and neutropenia induced by EBV infectious mononucleosis. <i>International Journal of Hematology</i> , 2010, 91, 326-327.	1.6	8
72	Essential roles of VLA-4 in the hematopoietic system. <i>International Journal of Hematology</i> , 2010, 91, 569-575.	1.6	41

#	ARTICLE	IF	CITATIONS
73	T cell acute lymphoblastic leukemia arising from familial platelet disorder. <i>International Journal of Hematology</i> , 2010, 92, 194-197.	1.6	43
74	IgG-associated immune thrombocytopenia in Waldenström macroglobulinemia. <i>International Journal of Hematology</i> , 2010, 92, 360-363.	1.6	6
75	CD30-positive anaplastic variant diffuse large B cell lymphoma: a rare case presented with cutaneous involvement. <i>International Journal of Hematology</i> , 2010, 92, 550-552.	1.6	9
76	A case of anaplastic large cell lymphoma, ALK positive, primary presented in the skin and relapsed with systemic involvement and leukocytosis after years of follow-up period. <i>International Journal of Hematology</i> , 2010, 92, 667-668.	1.6	9
77	EVI-1 interacts with histone methyltransferases SUV39H1 and G9a for transcriptional repression and bone marrow immortalization. <i>Leukemia</i> , 2010, 24, 81-88.	7.2	67
78	Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT. <i>Bone Marrow Transplantation</i> , 2010, 45, 1719-1727.	2.4	20
79	Efficacy and Safety of Modified Rituximab-ESHAP Therapy for Relapsed/Refractory B-Cell Lymphoma. <i>Journal of Chemotherapy</i> , 2010, 22, 54-57.	1.5	12
80	Post-transplant lymphoproliferative disorder after adult-to-adult living donor liver transplant: case series and review of literature. <i>Leukemia and Lymphoma</i> , 2010, 51, 1494-1501.	1.3	17
81	A Critical Role of Reactive Oxygen Species In the Generation of Megakaryocyte-Erythrocyte Progenitor Cells.. <i>Blood</i> , 2010, 116, 1605-1605.	1.4	1
82	Evi1 Is a Stem Cell-Specific Regulator of Self-Renewal Capacity In the Definitive Hematopoietic System. <i>Blood</i> , 2010, 116, 838-838.	1.4	0
83	Chronic myelomonocytic leukemia presenting severe uterine hemorrhage due to uterine infiltration of leukemic cells and early-stage endometrial adenocarcinoma. <i>Archives of Gynecology and Obstetrics</i> , 2009, 280, 1077-1078.	1.7	0
84	Acute eosinophilic pneumonia is a non-infectious lung complication after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2009, 89, 244-248.	1.6	20
85	Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders. <i>International Journal of Hematology</i> , 2009, 89, 592-599.	1.6	116
86	Interstitial pneumonia associated with progression of myelodysplastic syndrome. <i>International Journal of Hematology</i> , 2009, 89, 718-719.	1.6	2
87	Pbx1 is a downstream target of Evi-1 in hematopoietic stem/progenitors and leukemic cells. <i>Oncogene</i> , 2009, 28, 4364-4374.	5.9	58
88	Influence of Pretransplantation Serum Ferritin on Nonrelapse Mortality after Myeloablative and Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 195-204.	2.0	113
89	Successful Hematopoietic Stem Cell Transplantation from an HLA-Identical Sibling in a Patient with Aplastic Anemia after HLA-Haploidentical Living-Related Liver Transplantation for Fulminant Hepatitis. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 389-390.	2.0	15
90	AML1/Runx1 Is a Cytoplasmic Attenuator of NF-Kb Signaling: Implication in Pathogenesis and Targeted Therapy of AML1-Related Leukemia.. <i>Blood</i> , 2009, 114, 1962-1962.	1.4	1

#	ARTICLE	IF	CITATIONS
91	Impact On Survival and Treatment of Late-Onset Noninfectious Pulmonary Complications After Allogeneic Hematopoietic Stem Cell Transplantation.. Blood, 2009, 114, 3318-3318.	1.4	0
92	Monitoring Trough Concentration of Voriconazole Is Important to Ensure Successful Antifungal Therapy and to Avoid Hepatic Damage in Patients with Hematological Disorders.. Blood, 2009, 114, 4731-4731.	1.4	0
93	Genetic perturbation of the putative cytoplasmic membrane-proximal salt bridge aberrantly activates β 4 integrins. Blood, 2008, 112, 5007-5015.	1.4	31
94	A Non-Canonical Function of Zebrafish Telomerase Reverse Transcriptase Is Required for Developmental Hematopoiesis. PLoS ONE, 2008, 3, e3364.	2.5	47
95	An Extended Mathematical Model of Pathophysiology and Response to Treatment in Chronic Myelogenous Leukemia. Blood, 2008, 112, 4220-4220.	1.4	16
96	Evi-1 Interacts with Histone Methyltransferases for Transcription Repression and Bone Marrow Transformation.. Blood, 2008, 112, 2257-2257.	1.4	0
97	Pbx-1 Is a Direct Target of Evi-1 in Hematopoietic Stem/Progenitors and Leukemic Cells.. Blood, 2008, 112, 1192-1192.	1.4	1
98	Evi-1 Is a Direct Target of MLL Oncoproteins in Hematopoietic Stem Cells. Blood, 2008, 112, 3807-3807.	1.4	9
99	Pharmacokinetics of alemtuzumab after haploidentical HLA-mismatched hematopoietic stem cell transplantation using in vivo alemtuzumab with or without CD52-positive malignancies. American Journal of Hematology, 2006, 81, 875-879.	4.1	8
100	Notch1 oncoprotein antagonizes TGF β 2/Smad4-mediated cell growth suppression via sequestration of coactivator p300. Cancer Science, 2005, 96, 274-282.	3.9	65
101	Identification of Ki23819, a highly potent inhibitor of kinase activity of mutant FLT3 receptor tyrosine kinase. Leukemia, 2005, 19, 930-935.	7.2	23
102	Oligomerization of Evi-1 regulated by the PR domain contributes to recruitment of corepressor CtBP. Oncogene, 2005, 24, 6165-6173.	5.9	42
103	Clinical Significance of Peripheral Blood Erythroblastosis after Hematopoietic Stem Cell Transplantation. Leukemia and Lymphoma, 2004, 45, 2439-2443.	1.3	7
104	The Corepressor mSin3A Regulates Phosphorylation-Induced Activation, Intranuclear Location, and Stability of AML1. Molecular and Cellular Biology, 2004, 24, 1033-1043.	2.3	80
105	AML1 Is Functionally Regulated through p300-mediated Acetylation on Specific Lysine Residues. Journal of Biological Chemistry, 2004, 279, 15630-15638.	3.4	87
106	Leukemia-Related Transcription Factor TEL Is Negatively Regulated through Extracellular Signal-Regulated Kinase-Induced Phosphorylation. Molecular and Cellular Biology, 2004, 24, 3227-3237.	2.3	33
107	Increased incidence of acute graft-versus-host disease with the continuous infusion of cyclosporine A compared to twice-daily infusion. Bone Marrow Transplantation, 2004, 33, 549-552.	2.4	26
108	Predictors for severe cardiac complications after hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2004, 33, 1043-1047.	2.4	48

#	ARTICLE	IF	CITATIONS
109	Functional analysis of a dominant-negative $\hat{\nu}$ ETS TEL/ETV6 isoform. <i>Biochemical and Biophysical Research Communications</i> , 2004, 317, 1128-1137.	2.1	20
110	The transcriptionally active form of AML1 is required for hematopoietic rescue of the AML1-deficient embryonic para-aortic splanchnopleural (P-Sp) region. <i>Blood</i> , 2004, 104, 3558-3564.	1.4	53
111	Ki23819 (KRN383 $\hat{\nu}$ CHCl) Inhibits Kinase Activity of Wild Type and Mutant FLT3 Receptor Tyrosine Kinase In Vitro.. <i>Blood</i> , 2004, 104, 1168-1168.	1.4	0
112	Oligomerization of Evi-1 Contributes to Recruitment of Transcriptional Corepressor CtBP and Repression of TGF- $\hat{\nu}$ 2 Signaling.. <i>Blood</i> , 2004, 104, 2569-2569.	1.4	0
113	Male predominance among Japanese adult patients with late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2003, 32, 1175-1179.	2.4	43
114	Identification of a novel fusion gene, TTL, fused to ETV6 in acute lymphoblastic leukemia with t(12;13)(p13;q14), and its implication in leukemogenesis. <i>Leukemia</i> , 2003, 17, 1112-1120.	7.2	13
115	Should Young Patients with e19a2 Type BCR/ABL Rearrangement Undergo Stem Cell Transplantation?. <i>Leukemia and Lymphoma</i> , 2003, 44, 381-382.	1.3	3
116	Homeoprotein DLX-1 interacts with Smad4 and blocks a signaling pathway from activin A in hematopoietic cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 15577-15582.	7.1	42
117	Mutations of Chk2 in primary hematopoietic neoplasms. <i>Blood</i> , 2002, 99, 3075-3077.	1.4	38
118	Mutational Analyses of the AML1 Gene in Patients with Myelodysplastic Syndrome. <i>Leukemia and Lymphoma</i> , 2002, 43, 617-621.	1.3	6
119	Functional regulation of TEL by p38-induced phosphorylation. <i>Biochemical and Biophysical Research Communications</i> , 2002, 299, 116-125.	2.1	28
120	The t(3;21) fusion product, AML1/Evi-1 blocks AML1-induced transactivation by recruiting CtBP. <i>Oncogene</i> , 2002, 21, 2695-2703.	5.9	31
121	The corepressor CtBP interacts with Evi-1 to repress transforming growth factor $\hat{\nu}$ 2 signaling. <i>Blood</i> , 2001, 97, 2815-2822.	1.4	214
122	Mutations of the Smad4 gene in acute myelogeneous leukemia and their functional implications in leukemogenesis. <i>Oncogene</i> , 2001, 20, 88-96.	5.9	83
123	Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. <i>Blood</i> , 2000, 96, 3154-3160.	1.4	152
124	Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. <i>Blood</i> , 2000, 96, 3154-3160.	1.4	9
125	TLE, the Human Homolog of Groucho, Interacts with AML1 and Acts as a Repressor of AML1-Induced Transactivation. <i>Biochemical and Biophysical Research Communications</i> , 1998, 252, 582-589.	2.1	101
126	The AML1/ETO(MTG8) and AML1/Evi-1 Leukemia-Associated Chimeric Oncoproteins Accumulate PEBP2 $\hat{\nu}$ 2(CBF $\hat{\nu}$ 2) in the Nucleus More Efficiently Than Wild-Type AML1. <i>Blood</i> , 1998, 91, 1688-1699.	1.4	47

#	ARTICLE	IF	CITATIONS
127	The t(3;21) Fusion Product, AML1/Evi-1, Interacts With Smad3 and Blocks Transforming Growth Factor- β -Mediated Growth Inhibition of Myeloid Cells. <i>Blood</i> , 1998, 92, 4003-4012.	1.4	97
128	The AML1/ETO(MTG8) and AML1/Evi-1 Leukemia-Associated Chimeric Oncoproteins Accumulate PEBP2(CBF β) in the Nucleus More Efficiently Than Wild-Type AML1. <i>Blood</i> , 1998, 91, 1688-1699.	1.4	5
129	The t(3;21) Fusion Product, AML1/Evi-1, Interacts With Smad3 and Blocks Transforming Growth Factor- β -Mediated Growth Inhibition of Myeloid Cells. <i>Blood</i> , 1998, 92, 4003-4012.	1.4	7
130	Bronchiolitis obliterans organizing pneumonia after syngeneic bone marrow transplantation for acute lymphoblastic leukemia. <i>Bone Marrow Transplantation</i> , 1997, 19, 1251-1253.	2.4	31
131	The Extracellular Signal-Regulated Kinase Pathway Phosphorylates AML1, an Acute Myeloid Leukemia Gene Product, and Potentially Regulates Its Transactivation Ability. <i>Molecular and Cellular Biology</i> , 1996, 16, 3967-3979.	2.3	142